Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945448 | 1.00 | REN (0.54) | RENKLK5BCL2PTPN1PSEN1 | |
| SCHEMBL7312642 | 0.93 | KLK5 (0.52) | RENKLK5BCL2PTPN1PSEN1 | |
| SCHEMBL24066724 | 0.92 | KLK5 (0.50) | RENKLK5BCL2PTPN1PSEN1 | |
| SCHEMBL12103325 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL1104912 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL8222457 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL691498 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL19261937 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL1236129 | 0.91 | KLK5 (0.61) | RENKLK5PSEN1PSEN2APH1B | |
| SCHEMBL24066704 | 0.90 | KLK5 (0.50) | RENKLK5BCL2PTPN1PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | REN 796/4885KLK5 380/4885BCL2 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.